Teva UK turns to OTCs
This article was originally published in The Tan Sheet
Executive Summary
Teva UK Ltd. plans to launch beginning this fall more than 20 nonprescription drugs, including analgesics, gastrointestinals and allergy relief products. The branch of Teva Pharmaceutical Industries said Sept. 2 the drugs will be sold through general sales or pharmacy class. "Our generics portfolio is already the widest of any other U.K. generics supplier, and branching out into OTCs seems like the next logical step," said Kim Innes, Teva's commercial director. In the U.S., the firm remains largely on the OTC sidelines and recently licensed to Perrigo its rights to private-label versions of Sanofi-Aventis' Allegra once it switches OTC (1"The Tan Sheet" July 5, 2010)
You may also be interested in...
Perrigo Gains Pole Position In Private-Label Allegra Race
Perrigo cuts to the front of the queue for launching private-label versions of OTC Allegra, acquiring from Teva the exclusive U.S. sales and distribution rights to generic equivalents of the allergy drug
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.